Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge

Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge

Abstract SARS-CoV-2 is a viral respiratory pathogen responsible for the current global pandemic and the disease that causes COVID-19. All current WHO approved COVID-19 vaccines are administered through the muscular route. We have developed a prototype two-dose vaccine (BReC-CoV-2) by combining the R...

Full description

Bibliographic Details
Main Authors: Ting Y. Wong, Katherine S. Lee, Brynnan P. Russ, Alexander M. Horspool, Jason Kang, Michael T. Winters, M. Allison Wolf, Nathaniel A. Rader, Olivia A. Miller, Morgane Shiflett, Jerilyn Izac, David Varisco, Emel Sen-Kilic, Casey Cunningham, Melissa Cooper, Holly A. Cyphert, Mariette Barbier, Ivan Martinez, Justin R. Bevere, Robert K. Ernst, F. Heath Damron
Format: Article
Language:English
Published: Nature Portfolio 2022-03-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-022-00451-7

Internet

https://doi.org/10.1038/s41541-022-00451-7

Similar Items